These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 26942254

  • 1. NSAIDs and serious cardiovascular disorders: especially cox-2 inhibitors and diclofenac.
    Prescrire Int; 2016 Jan; 25(167):14-6. PubMed ID: 26942254
    [Abstract] [Full Text] [Related]

  • 2. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
    [Abstract] [Full Text] [Related]

  • 3. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C.
    Lancet; 2013 Aug 31; 382(9894):769-79. PubMed ID: 23726390
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, Daugherty JR, Arbogast PG, García-Rodríguez LA.
    Circ Cardiovasc Qual Outcomes; 2009 May 31; 2(3):155-63. PubMed ID: 20031832
    [Abstract] [Full Text] [Related]

  • 5. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
    Farkouh ME, Greenberg JD, Jeger RV, Ramanathan K, Verheugt FW, Chesebro JH, Kirshner H, Hochman JS, Lay CL, Ruland S, Mellein B, Matchaba PT, Fuster V, Abramson SB.
    Ann Rheum Dis; 2007 Jun 31; 66(6):764-70. PubMed ID: 17412741
    [Abstract] [Full Text] [Related]

  • 6. Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease.
    Hennekens CH, Borzak S.
    J Cardiovasc Pharmacol Ther; 2008 Mar 31; 13(1):41-50. PubMed ID: 18287589
    [Abstract] [Full Text] [Related]

  • 7. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.
    Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C.
    BMJ; 2006 Jun 03; 332(7553):1302-8. PubMed ID: 16740558
    [Abstract] [Full Text] [Related]

  • 8. Comparative cardiovascular safety of nonsteroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study.
    Dong YH, Chang CH, Wu LC, Hwang JS, Toh S.
    Br J Clin Pharmacol; 2018 May 03; 84(5):1045-1056. PubMed ID: 29468706
    [Abstract] [Full Text] [Related]

  • 9. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
    McGettigan P, Henry D.
    JAMA; 2006 Oct 04; 296(13):1633-44. PubMed ID: 16968831
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF, Hsiao FY, Wen YW, Tsai YW.
    Clin Ther; 2006 Nov 04; 28(11):1827-36. PubMed ID: 17213003
    [Abstract] [Full Text] [Related]

  • 11. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies.
    McGettigan P, Henry D.
    PLoS Med; 2011 Sep 04; 8(9):e1001098. PubMed ID: 21980265
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, Olson M, Mellein B, Hoexter G, Orloff J, Garaud JJ.
    Clin Ther; 2005 Aug 04; 27(8):1196-214. PubMed ID: 16199245
    [Abstract] [Full Text] [Related]

  • 13. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C.
    Circulation; 2006 Jun 27; 113(25):2906-13. PubMed ID: 16785336
    [Abstract] [Full Text] [Related]

  • 14. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S.
    Arthritis Rheum; 2006 May 27; 54(5):1378-89. PubMed ID: 16645966
    [Abstract] [Full Text] [Related]

  • 15. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA.
    Arthritis Rheum; 2006 Nov 27; 54(11):3390-8. PubMed ID: 17075817
    [Abstract] [Full Text] [Related]

  • 16. [Cardiovascular risk of non-steroidal anti-inflammatory drugs].
    Prozzi GR, Cañás M, Urtasun MA, Buschiazzo HO, Dorati CM, Mordujovich-Buschiazzo P.
    Medicina (B Aires); 2018 Nov 27; 78(5):349-355. PubMed ID: 30285927
    [Abstract] [Full Text] [Related]

  • 17. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
    Gunter BR, Butler KA, Wallace RL, Smith SM, Harirforoosh S.
    J Clin Pharm Ther; 2017 Feb 27; 42(1):27-38. PubMed ID: 28019014
    [Abstract] [Full Text] [Related]

  • 18. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study.
    Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, Folke F, Charlot M, Selmer C, Lamberts M, Bjerring Olesen J, Køber L, Hansen PR, Torp-Pedersen C, Gislason GH.
    Circulation; 2011 May 24; 123(20):2226-35. PubMed ID: 21555710
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.